William Blair Issues Pessimistic Estimate for LRMR Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Research analysts at William Blair decreased their Q1 2025 earnings per share estimates for shares of Larimar Therapeutics in a report issued on Monday, March 24th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($0.46) for the quarter, down from their previous forecast of ($0.35). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. William Blair also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.51) EPS, Q3 2025 earnings at ($0.53) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.01) EPS, Q1 2026 earnings at ($0.52) EPS, Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.52) EPS and FY2026 earnings at ($2.07) EPS.

Several other research firms also recently weighed in on LRMR. HC Wainwright increased their price target on Larimar Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Tuesday. Guggenheim reiterated a “buy” rating and issued a $26.00 target price on shares of Larimar Therapeutics in a research note on Tuesday. Truist Financial assumed coverage on shares of Larimar Therapeutics in a report on Wednesday, January 29th. They issued a “buy” rating and a $18.00 price objective for the company. Finally, Robert W. Baird lowered their target price on shares of Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a report on Tuesday. Eleven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $20.22.

Larimar Therapeutics Trading Down 2.6 %

NASDAQ:LRMR opened at $2.25 on Thursday. The firm’s 50 day moving average is $3.11 and its 200 day moving average is $5.18. Larimar Therapeutics has a 12 month low of $2.19 and a 12 month high of $11.20. The stock has a market capitalization of $143.57 million, a PE ratio of -1.96 and a beta of 0.99.

Larimar Therapeutics (NASDAQ:LRMR) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

Hedge Funds Weigh In On Larimar Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC grew its holdings in shares of Larimar Therapeutics by 15.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company’s stock worth $24,936,000 after purchasing an additional 876,431 shares in the last quarter. Blue Owl Capital Holdings LP increased its holdings in shares of Larimar Therapeutics by 11.7% in the 4th quarter. Blue Owl Capital Holdings LP now owns 4,653,040 shares of the company’s stock worth $18,007,000 after buying an additional 486,211 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its position in shares of Larimar Therapeutics by 23.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 2,100,000 shares of the company’s stock valued at $8,127,000 after buying an additional 399,123 shares in the last quarter. Alyeska Investment Group L.P. lifted its holdings in shares of Larimar Therapeutics by 38.6% during the 4th quarter. Alyeska Investment Group L.P. now owns 984,077 shares of the company’s stock worth $3,808,000 after acquiring an additional 273,920 shares during the last quarter. Finally, Renaissance Technologies LLC grew its position in Larimar Therapeutics by 45.1% in the fourth quarter. Renaissance Technologies LLC now owns 513,542 shares of the company’s stock worth $1,987,000 after acquiring an additional 159,700 shares in the last quarter. 91.92% of the stock is currently owned by institutional investors.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.